Mark Vandewalker

2.3k total citations · 1 hit paper
41 papers, 1.7k citations indexed

About

Mark Vandewalker is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Mark Vandewalker has authored 41 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Physiology, 24 papers in Pulmonary and Respiratory Medicine and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Mark Vandewalker's work include Asthma and respiratory diseases (33 papers), Respiratory and Cough-Related Research (16 papers) and Inhalation and Respiratory Drug Delivery (16 papers). Mark Vandewalker is often cited by papers focused on Asthma and respiratory diseases (33 papers), Respiratory and Cough-Related Research (16 papers) and Inhalation and Respiratory Drug Delivery (16 papers). Mark Vandewalker collaborates with scholars based in United States, Germany and Netherlands. Mark Vandewalker's co-authors include Petra Moroni-Zentgraf, Michael Engel, Eric D. Bateman, Huib A.M. Kerstjens, Ralf Sigmund, Ronald Dahl, Pierluigi Paggiaro, Ekkehard Beck, Wolfgang Seibold and Edwin A. Bronsky and has published in prestigious journals such as New England Journal of Medicine, PEDIATRICS and CHEST Journal.

In The Last Decade

Mark Vandewalker

39 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy

2012 476 citations Huib A.M. Kerstjens, Michael Engel et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Vandewalker United States	12	1.4k	1.1k	413	256	149	41	1.7k
M. Bresciani Italy	13	650 0.5×	300 0.3×	713 1.7×	150 0.6×	116 0.8×	25	1.1k
Eskil Kreiner‐Møller Denmark	15	692 0.5×	427 0.4×	176 0.4×	55 0.2×	105 0.7×	22	1.2k
I. Chanal France	18	1.1k 0.8×	339 0.3×	1.2k 3.0×	197 0.8×	151 1.0×	29	1.6k
Martín Penagos United Kingdom	23	1.3k 1.0×	265 0.2×	1.7k 4.1×	67 0.3×	128 0.9×	47	1.9k
Alessia Marseglia Italy	16	326 0.2×	240 0.2×	206 0.5×	119 0.5×	75 0.5×	42	633
Paul Porter United States	15	441 0.3×	246 0.2×	166 0.4×	111 0.4×	171 1.1×	29	979
Manuel E. Soto-Quirós Costa Rica	19	1.0k 0.7×	474 0.4×	253 0.6×	17 0.1×	116 0.8×	28	1.4k
Gail Shapiro United States	13	448 0.3×	281 0.2×	297 0.7×	104 0.4×	88 0.6×	21	699
Mariangela Tosca Italy	16	466 0.3×	249 0.2×	384 0.9×	29 0.1×	50 0.3×	36	682
Duncan Wilson United Kingdom	15	1.2k 0.9×	172 0.2×	1.3k 3.0×	21 0.1×	61 0.4×	31	1.6k

Countries citing papers authored by Mark Vandewalker

Since Specialization

Citations

This map shows the geographic impact of Mark Vandewalker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Vandewalker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Vandewalker more than expected).

Fields of papers citing papers by Mark Vandewalker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Vandewalker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Vandewalker. The network helps show where Mark Vandewalker may publish in the future.

Co-authorship network of co-authors of Mark Vandewalker

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Vandewalker. A scholar is included among the top collaborators of Mark Vandewalker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Vandewalker. Mark Vandewalker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vrijlandt, Elianne J.L.E., Georges El Azzi, Mark Vandewalker, et al.. (2018). Safety and efficacy of tiotropium in children aged 1–5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 6(2). 127–137. 49 indexed citations

Casale, Thomas B., Eric D. Bateman, Mark Vandewalker, et al.. (2017). Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. The Journal of Allergy and Clinical Immunology In Practice. 6(3). 923–935.e9. 59 indexed citations

Vandewalker, Mark, Eckard Hamelmann, Michael Engel, et al.. (2017). Once-daily Tiotropium Respimat® Add-on Therapy Has a Safety Profile Comparable with Placebo in Children and Adolescents. Journal of Allergy and Clinical Immunology. 139(2). AB94–AB94. 3 indexed citations

Kerstjens, Huib A.M., Petra Moroni-Zentgraf, Donald P. Tashkin, et al.. (2016). Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respiratory Medicine. 117. 198–206. 76 indexed citations

Hamelmann, Eckard, Eric D. Bateman, Christian Vogelberg, et al.. (2016). Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. Journal of Allergy and Clinical Immunology. 138(2). 441–450.e8. 106 indexed citations

Hamelmann, Eckard, Jonathan A. Bernstein, Mark Vandewalker, et al.. (2016). A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. European Respiratory Journal. 49(1). 1601100–1601100. 78 indexed citations

Bisgaard, Hans, Mark Vandewalker, LeRoy M. Graham, et al.. (2016). Safety of tiotropium in pre-school children with symptomatic persistent asthma. PA315–PA315. 4 indexed citations

Vogelberg, Christian, Olaf Schmidt, Eckard Hamelmann, et al.. (2016). LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat^®add-on therapy in children with moderate symptomatic asthma. PA4399–PA4399. 2 indexed citations

Dahl, Ronald, Thomas B. Casale, Mark Vandewalker, et al.. (2015). Once-Daily Tiotropium Respimat Reduces Risk of Severe Asthma Exacerbation and Asthma Worsening in Symptomatic Asthma, Independent of Allergic and Inflammatory Status. CHEST Journal. 148(4). 671A–671A. 3 indexed citations

10.

Vandewalker, Mark, et al.. (2015). Once-Daily Tiotropium Respimat Add-on to Inhaled Corticosteroids Over 1 Year Improves Lung Function in Adolescent Patients With Moderate Symptomatic Asthma, Independent of Patients Baseline Characteristics. CHEST Journal. 148(4). 720A–720A. 1 indexed citations

11.

Vogelberg, Christian, Michael E. Engel, Petra Moroni-Zentgraf, et al.. (2014). Once-Daily Tiotropium Respimat Add-On to Medium-Dose ICS Is an Efficacious 24-Hour Bronchodilator in Adolescent Patients With Symptomatic Asthma. CHEST Journal. 146(4). 698A–698A. 1 indexed citations

12.

Vandewalker, Mark, Eli O. Meltzer, Michael Engel, et al.. (2014). Safety and Tolerability of Once-Daily Tiotropium Respimat Add-On to at Least ICS: Results From Five Phase III Trials in Adult Patients With Symptomatic Asthma. CHEST Journal. 146(4). 1A–1A. 1 indexed citations

13.

Vogelberg, Christian, Michael Engel, Petra Moroni-Zentgraf, et al.. (2014). Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: A randomised dose-ranging study. Respiratory Medicine. 108(9). 1268–1276. 78 indexed citations

14.

Price, David, Michael E. Engel, Hendrik Schmidt, et al.. (2014). S91 Once-daily tiotropium Respimat(R) add-on to ICS + LABA improves symptom control and reduces exacerbations in patients with symptomatic asthma. Thorax. 69(Suppl 2). A49–A50. 1 indexed citations

15.

Hamelmann, Eckard, Attilio Boner, Jonathan A. Bernstein, et al.. (2014). 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma. 44. 1889. 3 indexed citations

16.

Kerstjens, Huib A.M., Michael Engel, Ronald Dahl, et al.. (2012). Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. New England Journal of Medicine. 367(13). 1198–1207. 476 indexed citations breakdown →

17.

Kerstjens, Huib A.M., Ronald Dahl, Ekkehard Beck, et al.. (2012). Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines. 40. 1796.

18.

Davis, Ray S., Mark Vandewalker, Patricia S. Hutcheson, & Raymond G. Slavin. (2006). Facial angioedema in children due to ladybug (Harmonia axyridis) contact: 2 case reports. Annals of Allergy Asthma & Immunology. 97(4). 440–442. 9 indexed citations

19.

Allen, David B., Edwin A. Bronsky, Craig LaForce, et al.. (1998). Growth in asthmatic children treated with fluticasone propionate. The Journal of Pediatrics. 132(3). 472–477. 141 indexed citations

20.

Vandewalker, Mark, et al.. (1989). Hypereosinophilia, neurologic, and gastrointestinal symptoms after bee-pollen ingestion. Journal of Allergy and Clinical Immunology. 83(4). 793–796. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact